Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

24 juin 2025 15h59 HE | Source: Abvance Therapeutics

Abvance Therapeutics Secures Strategic Seed Financing & Leadership Expansion at ADA Scientific Sessions

Abvance closes seed round led by Zubi Capital to advance glucagon-based therapies aimed at preventing hypoglycemia in people with diabetes.
21 juin 2025 13h50 HE | Source: Abvance Therapeutics

Abvance Therapeutics Announces Presentation of Human Clinical Data at the 85th Scientific Sessions of the American Diabetes Association

Abvance presents first-in-human data on insulin-glucagon co-dosing in T1D, demonstrating a novel approach to help prevent hypoglycemia
10 sept. 2024 09h00 HE | Source: Abvance Therapeutics

Abvance Therapeutics Announces $3.9M Program Related Investment from the Helmsley Charitable Trust to Support Development of Its Novel Insulin and Glucagon Combined Formulation

Abvance is developing ABV100, a proprietary, clinically validated combination of insulin and glucagon with a goal of improving glycemic control while reducing hypoglycemia for people with diabetes who...